Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer. - Dassen MG; Tree AC; Wiersema L; Neijndorff B; de Ruiter P; van der Linden J; Mitchell A; Dunlop A; Alexander S; Breitkreutz DY; Cooper S; Janssen T; et al. (International journal of radiation oncology, biology, physics, 2026)